$3.06
-0.10-3.16%
Benzinga
Benzinga
Benzinga
火曜日, 10 13
Benzinga
© 2026 Benzinga | All Rights Reserved
C4 Therapeutics (CCCC) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.23 | $-0.25 | $-0.41 | $-0.42 |
| Actual | $-0.18 | $-0.20 | $-0.18 | $-0.44 |
| Surprise | +21.7% | +20.0% | +56.1% | -4.76% |
| Revenue | ||||
| Estimate | $4.4M | $4.8M | $4.6M | $6.4M |
| Actual | $6.6M | $6.2M | $11.0M | $11.2M |
| Surprise | +50.9% | +27.3% | +139.1% | +76.3% |
| Metric | Q3 '26E | Q4 '26E |
|---|---|---|
| Earnings Per Share (Non-GAAP) | ||
| Consensus | $-0.21 | $-0.26 |
| Revenue | ||
| Consensus | $8.9M | $5.3M |
| 会計四半期 | 報告日 | 実質EPS | 推定EPS | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 11, 2026 | $-0.18 | $-0.23 | 21.7 % |
| Q1 | May 12, 2026 | $-0.20 | $-0.25 | 20.0 % |
| Q4 | Feb 26, 2026 | $-0.18 | $-0.41 | 56.1 % |
| Q3 | Nov 6, 2025 | $-0.44 | $-0.42 | -4.76 % |
| 会計四半期 | 報告日 | 実際の収益 | 推定収益 | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 11, 2026 | $6.64M | $4.40M | 50.9 % |
| Q1 | May 12, 2026 | $6.15M | $4.83M | 27.3 % |
| Q4 | Feb 26, 2026 | $11.02M | $4.61M | 139.1 % |
| Q3 | Nov 6, 2025 | $11.23M | $6.37M | 76.3 % |